Post-earnings recap
Reported
Mon, Mar 12, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Rhythm Pharmaceuticals reported a loss per share of $-0.41, but the stock saw a slight increase of 0.22% following the earnings release. The lack of revenue details and guidance may have led to a cautious reaction from investors. However, the stock's modest rise suggests some investors remain optimistic about the company's future potential.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management maintained a neutral tone during the call, emphasizing ongoing projects. No specific guidance was provided for the upcoming quarters.
Management did not provide specific guidance for future quarters.
The call focused on ongoing projects and future potential.